期刊
CLINICAL LUNG CANCER
卷 19, 期 1, 页码 84-92出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2017.06.016
关键词
Antiangiogenesis; BAC; Bronchioloalveolar; EGFR; Lepidic; Never-smoker
类别
资金
- National Institutes of Health (NIH)/National Cancer Institute (NCI)/National Clinical Trials Network (NCTN) [CA180888, CA180819, CA180846, CA180834, CA180818]
- NIH/NCI Community Oncology Research Program (NCORP) [CA189860, CA189808, CA189821, CA189872, CA189954, CA189830, CA189848, CA189971, CA189953, CA189858]
- Genentech, a member of the Roche Group
- NIH/NCI/NCTN [CA180888, CA180819, CA180846]
- NIH/NCI NCORP [CA189860, CA189808, CA189821, CA189872, CA189848, CA189971, CA189953, CA189822, CA189997]
- NIH/NCI legacy [CA32102, CA38926, CA12644, CA73590, CA45450, CA58416, CA46282, CA46136, CA16385, CA35119]
- NATIONAL CANCER INSTITUTE [U10CA012644, UG1CA189808, UG1CA189830, UG1CA189997, U10CA032102, U10CA180834, U10CA035119, UG1CA189954, UG1CA189822, U10CA046282, U10CA180888, U10CA038926, U10CA016385, UG1CA189858, UG1CA189848, UG1CA233324, U10CA180846, UG1CA189971, UG1CA189953, UG1CA189821, U10CA180818, U10CA180819, U10CA058416, UG1CA189872, U10CA073590, UG1CA189860, U10CA045450] Funding Source: NIH RePORTER
Paired phase II trials, Southwestern Oncology Group S0635 and S0636, administered erlotinib/bevacizumab to 84 patients with advanced bronchioloalveolar carcinoma or 85 never smokers with advanced lung adenocarcinoma, respectively. Efficacy, in particular, the primary endpoint of overall survival, well exceeded previous benchmarks, and the combination demonstrated no unexpected toxicity challenges. These results suggest that the erlotinib/bevacizumab combination might confer a clinical benefit for selected patients. Background: Before mutation testing of the epidermal growth factor receptor (EGFR) gene was recognized as highly associated with the activity of EGFR tyrosine kinase inhibitors (TKIs), clinically defined patient populations with bronchioloalveolar carcinoma (BAC) and never smokers were identified as likely to benefit from EGFR TKIs. From preclinical and clinical data suggesting potentially improved efficacy with a combination of an EGFR TKI and the antiangiogenic agent bevacizumab, the Southwestern Oncology Group (SWOG) initiated paired phase II trials to evaluate the combination of erlotinib/bevacizumab in patients with advanced BAC (SWOG S0635) or never smokers with advanced lung adenocarcinoma (SWOG S0636). Materials and Methods: Eligible patients with BAC or adenocarcinoma with BAC features (SWOG S0635) or never smokers with advanced lung adenocarcinoma (SWOG S0636) received erlotinib 150 mg/day with bevacizumab 15 mg/kg until progression or prohibitive toxicity. Never smokers with BAC were preferentially enrolled to SWOG S0636. The primary endpoint for both trials was overall survival. Results: A total of 84 patients were enrolled in the SWOG S0635 trial and 85 in the SWOG S0636 trial. The objective response rate was 22% (3% complete response) in the SWOG S0635 trial and 50% (38% confirmed; 3% complete response) in the SWOG S0636 trial. The median progression-free survival was 5 and 7.4 months in the S0635 and S0636 trials, respectively. The median overall survival was 21 and 29.8 months, respectively. Toxicity consisted mainly of rash and diarrhea in both trials. Conclusion: Although the field has moved toward molecular, rather than clinical, selection of patients as optimal candidates for EGFR TKI therapy, these results support the hypothesis that a subset of patients in whom erlotinib is particularly active could receive an incremental benefit from the addition of bevacizumab. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据